NeurogesX Inc.

San Carlos, Calif. • 650-508-2116 •

Exchange and Ticker: Nasdaq: NGSX

Filing Range: 4.00M shares @ $13.00 to $15.00

Offering Price: $11.00

Close on First Day: $10.65

Offering Size: $44.00M

Shares Outstanding: 12,487,898M

Underwriter: Morgan Stanley

Co-managers: Pacific Growth Equities Inc./ Lazard Capital Markets/ Susquehanna Financial Group

Company Counsel: Wilson Sonsini Goodrich & Rosati

Manager Counsel: Davis Polk & Wardwell

Auditor: Ernst & Young LLP

Market Capitalization on 5/31/07: $101.15M

Close price at current month end: $8.10


Develops and commercializes treatments for nerve signaling disorders. The company also develops and produces pharmaceuticals for intractable pain relief. NeurogesX’s initial products are focused on the treatment of chronic pain in the areas of postherpetic neuralgia (PHN), painful HIV-associated sensory neuropathy (HIV-AN) and painful diabetic neuropathy (PDN). Competitors include Lidoderm, Endo Pharmaceuticals, Pfizer, GlaxoSmithKline, Merck & Co., Novartis AG and Eli Lilly.


Alta Partners, ARCH Venture Partners, Diamond Capital Company, Life Science Ventures, Mitsubishi International Corp., Montreux Equity Partners, Teachers Insurance & Annuity Association College Retirement, Walden International.

Source: Thomson Financial